These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 19781418)

  • 41. Randomized comparison of the effects of ASA plus clopidogrel versus ASA alone on early platelet activation in acute coronary syndromes with elevated high-sensitivity C-reactive protein and soluble CD40 ligand levels.
    Vavuranakis M; Latsios G; Aggelis D; Bosinakou I; Karambelas I; Tousoulis D; Toutouzas K; Stefanadis C
    Clin Ther; 2006 Jun; 28(6):860-71. PubMed ID: 16860169
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of Switching From Prasugrel to Clopidogrel Shortly After a Percutaneous Coronary Intervention Without a Loading Dose of Clopidogrel.
    Mizrahi E; Suryadevara RS; Barn K; Boga G; Akram MM; Ismail-Sayed I; Henry YM; Troup MA; Berger PB
    J Invasive Cardiol; 2015 Dec; 27(12):543-6. PubMed ID: 26378415
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of high loading and maintenance dose of clopidogrel within the first 15 days after percutaneous coronary intervention on patient outcome.
    Lemesle G; Delhaye C; Sudre A; Broucqsault D; Rosey G; Bauters C; Lablanche JM
    Am Heart J; 2009 Feb; 157(2):375-82. PubMed ID: 19185648
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rosuvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of myocardial periprocedural necrosis: the ROMA trial.
    Sardella G; Conti G; Donahue M; Mancone M; Canali E; De Carlo C; Di Roma A; Calcagno S; Lucisano L; Fedele F
    Catheter Cardiovasc Interv; 2013 Jan; 81(1):E36-43. PubMed ID: 22517610
    [TBL] [Abstract][Full Text] [Related]  

  • 45. One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel.
    Schömig A; Schmitt C; Dibra A; Mehilli J; Volmer C; Schühlen H; Dirschinger J; Dotzer F; ten Berg JM; Neumann FJ; Berger PB; Kastrati A;
    Eur Heart J; 2005 Jul; 26(14):1379-84. PubMed ID: 15734767
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Protective effect of lipid microspheres 1 on myocardial injury following elective percutaneous coronary intervention in patients with angina pectoris: a pilot study.
    Chu-fan L; Xing W; Xun H; Gui-fu W; Cheng-heng H; Zhi-min D
    J Cardiovasc Med (Hagerstown); 2011 Nov; 12(11):790-4. PubMed ID: 21934521
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Clinical significance of early percutaneous coronary intervention in patients with Braunwald III-B type unstable angina pectoris].
    Nozaki K; Nakao K; Horiuchi K; Kasanuki H; Honda T
    J Cardiol; 2003 Jun; 41(6):263-70. PubMed ID: 12845880
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy.
    Mehta SR; Bassand JP; Chrolavicius S; Diaz R; Fox KA; Granger CB; Jolly S; Rupprecht HJ; Widimsky P; Yusuf S;
    Am Heart J; 2008 Dec; 156(6):1080-1088.e1. PubMed ID: 19033002
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.
    Wiviott SD; Trenk D; Frelinger AL; O'Donoghue M; Neumann FJ; Michelson AD; Angiolillo DJ; Hod H; Montalescot G; Miller DL; Jakubowski JA; Cairns R; Murphy SA; McCabe CH; Antman EM; Braunwald E;
    Circulation; 2007 Dec; 116(25):2923-32. PubMed ID: 18056526
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstream TIrofiban, in cath Lab Downstream Abciximab (CLOTILDA) study.
    Leoncini M; Toso A; Maioli M; Bellandi F; Badia T; Politi A; De Servi S; Dabizzi RP
    Am Heart J; 2005 Sep; 150(3):401. PubMed ID: 16169315
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of higher clopidogrel loading and maintenance dose to standard dose on platelet function and outcomes after percutaneous coronary intervention using drug-eluting stents.
    Abuzahra M; Pillai M; Caldera A; Hartley WB; Gonzalez R; Bobek J; Dokainish H; Lakkis N
    Am J Cardiol; 2008 Aug; 102(4):401-3. PubMed ID: 18678295
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Periprocedural use of tirofiban in elective percutaneous coronary intervention for long coronary lesions in stable patients with overlapping drug-eluting stents--the PETITION study: a prospective, randomized, multicenter study.
    Zhang Q; Wang XL; Liao ML; Hu J; Yang ZK; Ding FH; Zhang JS; Du R; Zhu TQ; Shen WF; Zhang RY
    Catheter Cardiovasc Interv; 2015 Mar; 85 Suppl 1():762-9. PubMed ID: 25630513
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical outcomes of high on-treatment platelet reactivity in Koreans receiving elective percutaneous coronary intervention (from results of the CROSS VERIFY study).
    Park KW; Jeon KH; Kang SH; Oh IY; Cho HJ; Lee HY; Kang HJ; Park SK; Koo BK; Oh BH; Park YB; Kim HS
    Am J Cardiol; 2011 Dec; 108(11):1556-63. PubMed ID: 21880289
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: do we need more aggressive dosing regimens in unstable angina?
    Soffer D; Moussa I; Harjai KJ; Boura JA; Dixon SR; Grines CL; O'Neill WW; Roubin GS; Moses JW
    Catheter Cardiovasc Interv; 2003 May; 59(1):21-5. PubMed ID: 12720236
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
    Parodi G; Marcucci R; Valenti R; Gori AM; Migliorini A; Giusti B; Buonamici P; Gensini GF; Abbate R; Antoniucci D
    JAMA; 2011 Sep; 306(11):1215-23. PubMed ID: 21934054
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention.
    Mangiacapra F; Barbato E; Patti G; Gatto L; Vizzi V; Ricottini E; D'Ambrosio A; Wijns W; Di Sciascio G
    JACC Cardiovasc Interv; 2010 Mar; 3(3):318-23. PubMed ID: 20298992
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
    Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD
    J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term versus short-term clopidogrel therapy in patients undergoing coronary stenting (from the Randomized Argentine Clopidogrel Stent [RACS] trial).
    Bernardi V; Szarfer J; Summay G; Mendiz O; Sarmiento R; Alemparte MR; Gabay J; Berger PB
    Am J Cardiol; 2007 Feb; 99(3):349-52. PubMed ID: 17261396
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety of reloading prasugrel in addition to clopidogrel loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
    Loh JP; Pendyala LK; Kitabata H; Torguson R; Chen F; Kent KM; Satler LF; Suddath WO; Pichard AD; Waksman R
    Am J Cardiol; 2013 Mar; 111(6):841-5. PubMed ID: 23273719
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardial infarction (ASSIST).
    Le May MR; Wells GA; Glover CA; So DY; Froeschl M; Marquis JF; O'Brien ER; Turek M; Thomas A; Kass M; Jadhav S; Labinaz M
    Circ Cardiovasc Interv; 2009 Aug; 2(4):330-8. PubMed ID: 20031736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.